Latest / My Life On GLP1 / S13.E4: My Life On GLP1 - The Twelve Percent! Real Stats of Side Effects and Usage
Transcript
- 0:03SPEAKER_00: Hey everyone, welcome back to my life on a GLP 1.
- 0:07SPEAKER_00: I'm your host, Scott Johnson.
- 0:10SPEAKER_00: Today we are discussing some fascinating statistics about GLP1 usage.
- 0:15SPEAKER_00: I went down this rabbit hole of data and decided that today's episode is called the 12%.
- 0:22SPEAKER_00: With me as always is my trusted co-host, Sarah.
- 0:26SPEAKER_01: Hi everyone, glad to be here.
- 0:28SPEAKER_01: Today we're diving into some pretty eye-opening numbers about GLP 1 medications that'll make you realize just how massive this phenomenon has become.
- 0:37SPEAKER_00: Massive is right.
- 0:39SPEAKER_00: So get this.
- 0:40SPEAKER_00: From 2017 to 2024, there's been a fortyfold increase in GLP one usage.
- 0:46SPEAKER_01: An increase of forty times.
- 0:48SPEAKER_01: That is incredible.
- 0:49SPEAKER_00: That means one in eight Americans has now tried these medications.
- 0:53SPEAKER_00: We're talking about over forty million people.
- 0:57SPEAKER_00: We are all in the twelve percent of Americans who have ever tried a GLP one medication.
- 1:04SPEAKER_01: That's incredible.
- 1:05SPEAKER_01: And speaking from experience, I can tell you why some people don't stick with it.
- 1:09SPEAKER_01: The side effects are let's just say they're memorable.
- 1:12SPEAKER_00: Oh yeah, no doubt.
- 1:14SPEAKER_00: So here's the breakdown.
- 1:16SPEAKER_00: About forty percent of people experience nausea, which honestly makes sense because that's how these drugs work, right?
- 1:23SPEAKER_00: They slow down your stomach.
- 1:25SPEAKER_01: Mm-hmm.
- 1:26SPEAKER_01: And then there's the digestive lottery.
- 1:28SPEAKER_01: Twenty-one percent get diarrhea, twenty percent get constipation.
- 1:31SPEAKER_00: Wait, did you just call it the digestive lottery?
- 1:34SPEAKER_00: That's hilarious.
- 1:35SPEAKER_00: I should be rich and retired by now based on my experiences.
- 1:39SPEAKER_01: Exactly.
- 1:40SPEAKER_01: It's like your digestive system just throws up its hands and says, I don't know what to do anymore, and about sixteen percent experience vomiting.
- 1:48SPEAKER_00: The really striking thing is that 73% of people using GLP1s experience some kind of gastrointestinal side effect compared to 47% on placebo.
- 2:00SPEAKER_01: Right, so it's not just in your head these drugs genuinely mess with your digestive system, but here's something that surprised me.
- 2:07SPEAKER_01: Only about 7% of people actually stop taking them because of side effects.
- 2:12SPEAKER_00: That tells you something about how effective people find them, right?
- 2:15SPEAKER_00: Like, yeah, I might throw up occasionally, but I'm losing weight.
- 2:20SPEAKER_00: Now, speaking of side effects, let's talk about managing them.
- 2:23SPEAKER_00: A lot of people don't realize there are strategies that can really help minimize these issues.
- 2:28SPEAKER_01: Oh, absolutely.
- 2:29SPEAKER_01: Like starting with smaller doses and gradually increasing what doctors call titrating up, and eating smaller, more frequent meals can really help with the nausea.
- 2:38SPEAKER_00: Exactly.
- 2:39SPEAKER_00: And timing matters too.
- 2:40SPEAKER_00: Taking the injection at night can sometimes help people sleep through the worst of the initial side effects.
- 2:46SPEAKER_00: Plus, staying hydrated is crucial.
- 2:49SPEAKER_01: Now let's talk about the elephant in the room.
- 2:51SPEAKER_01: Cost.
- 2:52SPEAKER_01: These medications can run anywhere from 500 to 1,200 per month without insurance coverage.
- 2:58SPEAKER_00: That's staggering.
- 2:59SPEAKER_00: And insurance coverage is all over the place.
- 3:02SPEAKER_00: Some plans cover it for diabetes, but not for weight loss, even though it's the same medication.
- 3:08SPEAKER_01: Right, and this has created this weird healthcare disparity where your diagnosis literally determines your access.
- 3:15SPEAKER_01: If you're diabetic, you might get it covered.
- 3:17SPEAKER_01: If you just need to lose weight for your health, you're potentially looking at over 14,000 a year out of pocket.
- 3:23SPEAKER_00: And this demand has created supply shortages.
- 3:26SPEAKER_00: Novo Nordisk and Eli Lilly literally cannot keep up with demand.
- 3:30SPEAKER_00: We've seen periodic shortages that last months.
- 3:34SPEAKER_01: Which brings up a crucial point.
- 3:35SPEAKER_01: What happens when you stop?
- 3:37SPEAKER_01: The research shows that most people regain about two-thirds of their lost weight within a year of discontinuation.
- 3:43SPEAKER_00: So we're potentially talking about a lifetime commitment.
- 3:46SPEAKER_00: That's a big decision when you factor in the cost and the fact that we don't have decades of long-term safety data yet.
- 3:54SPEAKER_01: But the research pipeline is exciting.
- 3:56SPEAKER_01: There are new formulations in development, oral versions, combination therapies, even longer acting injections that you might only need once a month.
- 4:04SPEAKER_00: And here's what's really fascinating.
- 4:06SPEAKER_00: Researchers are finding these drugs might have benefits beyond weight loss and diabetes.
- 4:12SPEAKER_00: There's promising research on cardiovascular protection, kidney disease, even addiction treatment.
- 4:19SPEAKER_01: Exactly.
- 4:20SPEAKER_01: Now there's one side effect that's particularly interesting, hair loss.
- 4:24SPEAKER_01: Overall it affects about 3% of users, but here's the kicker.
- 4:28SPEAKER_01: It hits women way harder.
- 4:30SPEAKER_01: 7.1% of women versus just 0.5% of men.
- 4:35SPEAKER_01: So ladies, you might want to stock up on some good leave-in shampoo and conditioner.
- 4:39SPEAKER_00: Or invest in a really good hat collection.
- 4:42SPEAKER_00: But on a more serious note, the safety profile overall seems pretty good.
- 4:47SPEAKER_00: Hospitalizations are less than 1% of reported cases.
- 4:52SPEAKER_01: That's reassuring, but here's what's not reassuring.
- 4:54SPEAKER_01: The quality issues with compounded versions.
- 4:57SPEAKER_01: We're seeing problems when people go off brand to save money.
- 5:00SPEAKER_00: Right.
- 5:01SPEAKER_00: And that brings up the bigger picture here.
- 5:03SPEAKER_00: What we're really witnessing is one of the largest real-world medical experiments in history.
- 5:08SPEAKER_01: That's both exciting and a little terrifying, isn't it?
- 5:11SPEAKER_00: Absolutely.
- 5:12SPEAKER_00: We're learning in real time about long-term effects, optimal dosing, who responds best.
- 5:17SPEAKER_00: It's fascinating, but also means we're all kind of pioneers.
- 5:21SPEAKER_01: Data is showing that discontinuation rates on Zetbound or Manjaro increase with the dose.
- 5:26SPEAKER_01: Approximately 25% of people stop taking the 15 milligram dose compared to just 5.1% at the 5 milligram dose.
- 5:34SPEAKER_00: This suggests that for many people, there is a sweet spot where the benefits outweigh the discomfort, and crossing beyond that threshold becomes untenable.
- 5:44SPEAKER_01: I hope everyone finds their sweet spot on these medications.
- 5:46SPEAKER_01: Remember, always consult with your healthcare provider about any medication decisions.
- 5:51SPEAKER_01: In the meantime, I hope you found some of today's data interesting and encourage you to add more data to our podcast by giving us a five star rating and review wherever you stream.
- 6:03SPEAKER_01: Tell us, Scott, do you have any final advice for our listeners today?
- 6:07SPEAKER_00: For anyone considering these medications, these numbers provide a reality check.
- 6:12SPEAKER_00: They strip away both the utopian promises of effortless weight loss and the catastrophic warnings that every user will face dire consequences.
- 6:22SPEAKER_00: The truth, as usual, lives in the middle, expressed in percentages and ratios that represent real humans having real experiences.
- 6:33SPEAKER_00: Thanks for listening.
- 6:34SPEAKER_00: I encourage you to visit my website at mylife on GLP one dot com for the latest tips, tricks, and articles to guide you along your journey.
- 6:44SPEAKER_00: On behalf of Sarah, I'm Scott Johnson.
- 6:47SPEAKER_00: Give us a follow so you can stay tuned with more insights from the front lines of this medication revolution.
- 6:56SPEAKER_00: Congratulations on being in the twelve percent and always remember to love your journey.